A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Rilvegostomig (Primary) ; Capecitabine; Cisplatin; Gemcitabine; Gimeracil/oteracil/tegafur
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIDE-(Biliary01); ARTEMIDE-Bil01
- Sponsors AstraZeneca
Most Recent Events
- 04 Jun 2024 Trial design assessing the efficacy and tolerability of rilvegostomig IV every three weeks versus placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1 [tegafur/gimeracil/oteracil] or gemcitabine/cisplatin) as adjuvant treatment in patients with BTC after curative intent resection were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 02 Apr 2024 Planned End Date changed from 24 Sep 2030 to 30 Sep 2030.
- 02 Apr 2024 Planned primary completion date changed from 25 Jun 2029 to 29 Jun 2029.